Article Information
PMID
Published By
Print ISSN
0250-7005
Online ISSN
1791-7530
History
- Received January 15, 2019
- Revision received February 22, 2019
- Accepted February 27, 2019
- Published online April 5, 2019.
Copyright & Usage
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
Author Information
- MARKOS ANTONOPOULOS1⇑,
- STEFAAN W. VAN GOOL2,
- DIMITRA DIONYSIOU1,
- NORBERT GRAF3 and
- GEORGIOS STAMATAKOS1
- 1Institute of Communication and Computer Systems, School of Electrical and Computer Engineering, National Technical University of Athens, Athens, Greece
- 2Immuno-Oncologic Center Köln, Köln, Germany
- 3Department of Pediatric Oncology and Hematology, Saarland University Medical Center, Homburg an der Saar, Germany
- Correspondence to: Markos Antonopoulos, Institute of Communication and Computer Systems, School of Electrical and Computer Engineering, National Technical University of Athens, Iroon Polytechniou Str. 9, 157 80 Zografou, Athens, Greece. E-mail: markos523{at}yahoo.gr
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Palliative Radiotherapy of Primary Glioblastoma
- Prognostic Factors of Local Control and Survival in Patients Irradiated for Glioblastoma Multiforme (GBM)
- Re-Irradiation for Recurrent Glioblastoma Multiforme
- Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells